Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 13;25(18):9899.
doi: 10.3390/ijms25189899.

Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status

Affiliations

Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status

Stacy Bedore et al. Int J Mol Sci. .

Abstract

The clinical outcome of patients with muscle-invasive bladder cancer (MIBC) is poor despite the approval of neoadjuvant chemotherapy or immunotherapy to improve overall survival after cystectomy. MIBC subtypes, immune, transcriptome, metabolomic signatures, and mutation burden have the potential to predict treatment response but none have been incorporated into clinical practice, as tumor heterogeneity and lineage plasticity influence their efficacy. Using the PRISMA statement, we conducted a systematic review of the literature, involving 135 studies published within the last five years, to identify studies reporting on the prognostic value of protein-based biomarkers for response to neoadjuvant therapy in patients with MIBC. The studies were grouped based on biomarkers related to molecular subtypes, cancer stem cell, actin-cytoskeleton, epithelial-mesenchymal transition, apoptosis, and tumor-infiltrating immune cells. These studies show the potential of protein-based biomarkers, especially in the spatial context, to reduce the influence of tumor heterogeneity on a biomarker's prognostic capability. Nevertheless, currently, there is little consensus on the methodology, reagents, and the scoring systems to allow reliable assessment of the biomarkers of interest. Furthermore, the small sample size of several studies necessitates the validation of potential prognostic biomarkers in larger multicenter cohorts before their use for individualizing neoadjuvant therapy regimens for patients with MIBC.

Keywords: bladder cancer; lineage plasticity; neoadjuvant therapy; prognostic markers; protein-based biomarkers; systematic review; tumor heterogeneity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram. Results from literature review. With the exclusion criteria of publications from the last 5 years, search strings resulted in 72 and 83 hits, for an initial sample size of 155. After the removal of duplicates, 135 articles were further analyzed, as shown in the flow diagram. Based on the inclusion parameters, and after full-text appraisal, 14 publications were selected for inclusion in this review.

Similar articles

Cited by

  • Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer.
    Attanasio G, Failla M, Poidomani S, Buzzanca T, Salzano S, Zizzo M, Palicelli A, Zanelli M, Koufopoulos N, Russo GI, Caltabiano R, Broggi G. Attanasio G, et al. Front Oncol. 2025 Jul 15;15:1546160. doi: 10.3389/fonc.2025.1546160. eCollection 2025. Front Oncol. 2025. PMID: 40735045 Free PMC article. Review.
  • Bladder cancer biomarkers.
    Godlewski D, Bartusik-Aebisher D, Czech S, Szpara J, Aebisher D. Godlewski D, et al. Explor Target Antitumor Ther. 2025 Mar 25;6:1002301. doi: 10.37349/etat.2025.1002301. eCollection 2025. Explor Target Antitumor Ther. 2025. PMID: 40135048 Free PMC article. Review.

References

    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Contieri R., Martini A., Mertens L.S., Giannatempo P., Hurle R., Witjes J.A., Ribal M.J., van Rhijn B.W., Malavaud B. The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma. Eur. Urol. Focus. 2024 doi: 10.1016/j.euf.2023.12.002. in press . - DOI - PubMed
    1. Soares A., Bourlon M.T., Wong A., Joshi A., Jardim D., Korbenfeld E., Karak F.E., Orlandi F., Sze H., Ansari J., et al. Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion. Clin. Genitourin. Cancer. 2024;22:467–475. doi: 10.1016/j.clgc.2024.01.001. - DOI - PubMed
    1. Williams S.B., Hudgins H.K., Ray-Zack M.D., Chamie K., Smaldone M.C., Boorjian S.A., Daneshmand S., Black P.C., Kamat A.M., Goebell P.J., et al. Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur. Urol. Oncol. 2019;2:119–125. doi: 10.1016/j.euo.2018.07.006. - DOI - PMC - PubMed
    1. Lokeshwar S.D., Lopez M., Sarcan S., Aguilar K., Morera D.S., Shaheen D.M., Lokeshwar B.L., Lokeshwar V.B. Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. Cancers. 2022;14:2578. doi: 10.3390/cancers14112578. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources